In a significant stride towards making advanced cancer treatment accessible to all, Ahmedabad-based pharma company Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach.

Out of 14 lakh newly diagnosed cancer patients in India, nearly 2.75 lakh patients are diagnosed with breast, ovarian, prostate and pancreatic cancers as per Globocan 2022 data. Amongst these patients, those who are diagnosed as homologous recombination deficiency (HRD) positive or with BRACA mutation need to be administered this PARP inhibitor which can delay the progression of the disease. IBYRA is a next gen targeted therapy for HRD positive and BRACA positive cancer patients.

To help identify the right patients and facilitate access, Zydus has collaborated with Bengaluru-based MedGenome for comprehensive HRD testing. This alongwith a year-long treatment of IBYRA has been capped at Rs 3 lakh as compared to the cost of around Rs 72 lakh by the innovator.